Type 1 Diabetes: Competitive Landscape to 2026
|出版日期||内容资讯||英文 48 Pages
|第一型糖尿病:市场竞争环境 (到2026年) Type 1 Diabetes: Competitive Landscape to 2026|
|出版日期: 2018年09月30日||内容资讯: 英文 48 Pages||
本报告提供第一型糖尿病 (T1D)的治疗药临床实验、上市预测相关分析，临床实验的整体发展情形 (各地区的明细，初期/后期阶段的产品，主要的赞助商等) ，及主要开发中产品临床实验趋势 (各临床实验阶段)，今后的市场规模的预测值，现在/未来的代表性企业的概要，今后的市场趋势预测等调查。
Type 1 Diabetes (T1D) is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which means that the body can no longer produce insulin. Type 1 Diabetes (T1D) can develop at any age, but is frequently observed in children and adolescents.Type 1 Diabetes (T1D) is the seventh most investigated indication within metabolic diseases by number of clinical trials, accounting for 8% of all clinical trials initiated since 1995.
Globally, Type 1 Diabetes (T1D) pipeline features 236 products across all stages of clinical development, with insulin and small molecules prominently featured in Phase III. Insulins, vaccines, and monoclonal antibodies dominate the early-stage pipeline.
Multiple big pharma developers (Novo Nordisk, Eli Lilly, and Sanofi) are investigating "smart insulin," insulin that can detect and respond to glucose levels. And for Stem Cell Therapy research, big pharma once again has a large presence, with AstraZeneca, Johnson and Johnson, Novo Nordisk, and Sanofi gearing up to develop novel treatments that target diabetes.
Overall, it is expected that new insulins and SGLT inhibitor approvals will drive Type 1 Diabetes market growth during the next decade.
The report "Type 1 Diabetes: Competitive Landscape to 2026", provides an assessment of the pipeline, clinical, and commercial landscape of Type 1 Diabetes along with an analysis of key market events and the future competitive environment.
This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include -